Our management’s extensive industry experience can accelerate your small molecule R&D and GMP program
Nicolas Fortin is a proven business leader, experienced Manager, entrepreneur and investor. He’s highly motivated by creating value through delivering strong results and surrounding himself with skilled and talented people and helping them thrive. His core management values are commitment, respect, teamwork, and transparency.
Accumulating almost 20 years of extensive experience, his career has been mostly centered towards the pharmaceutical industry in North America and Asia. He presently serves as President, General Manager and AdBoard Committee Member of Neopharm Labs.
In addition to his experience as CEO, he has managed multi-million dollar P&L and lead large teams of people. Nicolas worked within the technical operations department of Valeant Pharmaceutical International and Pharmascience, one of the top 5 generic pharmaceutical companies in Canada.
He has also had the opportunity to lead many acquisitions and integrations over the course of his career. In addition to steering many successful product launches and implementing a procurement process in Asia, he has developed a solid expertise in the integration of multiple businesses.
Nicolas recently lead Neopharm Labs to pass an important milestone in its growth strategy. He achieved outstanding growth beyond the Canadian border when he recently finalized the first U.S. acquisition for Neopharm Labs, Averica Discovery, a pharmaceutical company based in the Boston area. This achievement was made possible by leading a strong strategic plan and working with the right team of talented people.
Nicolas completed his Master in Business, Executive MBA, from McGill & HEC Montréal Universities, and earned a Bachelor’s Degree in Industrial Engineering from UQTR (Université du Québec à Trois-Rivières).
He is a member of L’Ordre des Ingénieurs du Québec and participates as an active member of Anges Québec, a network of 200 private investors that identifies, finances and coaches innovative Quebec enterprises with high growth potential.
Dr. Kiplinger has 25 years of experience in pharmaceutical and related industries, working extensively in the discovery and optimization of small molecule human and veterinary therapeutics. From 2001 through 2007, Dr. Kiplinger consulted with a variety of discovery technology companies on the optimization of chemistry discovery process. Previously, he founded the Gilson Center for Integrated Discovery Technology (CIDT) as a partnership development center responsible for high-speed chemistry and analysis products. From 1988 to 1998 at Pfizer, Dr. Kiplinger supported discovery chemistry activities by developing new applications for mass spectrometry and chromatography, in particular Open Access HPLC/MS and mass spectrometry-directed preparative chromatography.
Dr. Berger brings over 20 years of experience working in analytical contract research and instrumentation companies. Prior to joining Averica Discovery, Dr. Berger served as Project Manager at PCI Synthesis, a contract manufacturing organization (CMO), where she managed million dollar projects developing drug substances. Previously, she served as Vice President and Co-Founder of Pion, Inc., an instrumentation company and CRO, where she oversaw instrumentation sales, the CRO laboratory, and project management. In addition to her responsibilities, Dr. Berger was a key contributor to the development of Pion’s instruments and intellectual property. She also established new markets for the company, expanding their service offerings. Dr. Berger earned her Ph.D. in Chemistry from Penn State University.
Natasha Demberg is a Pharmaceutical Executive with 20+ years expertise in the development and application of Quality Management Systems throughout product life-cycle. She is skilled in leadership and management and has lead international multi-functional groups to address challenging global regulatory compliance issues. She has both hands-on expertise and a strategic view of all aspects of the pharmaceutical manufacturing process.
Natasha is presently the Vice President of Pharmaceutical Solutions at Neopharm Labs, a full service GMP analytical testing laboratory serving the Life Science industry where she is responsible for Business Development, and Customer Experience.
She is known for her dynamic leadership style and her ability to think strategically. She brings with her the tremendous mix of both technical expertise and regulatory knowledge.
Natasha’s career has included a wide range of successful leadership positions in Quality Organisations of several large companies in the pharmaceutical field. Initially as a chemist at Plantex Teva and Abbott Laboratory and later as Senior GMP Compliance Associate at Merck Frosst Canada, responsible for Quality aspect of Clinical manufacturing, and Head of Quality at Valeant Canada and Confab Laboratory responsible of entire Quality Operations.
Mickey joined Averica in 2009 after graduating from Merrimack College with a degree in Chemistry. His responsibilities started with small molecule purification and grew to include method development, system analysis for suitability, and project management. In the four years at Averica, Mickey became proficient in SFC, HPLC, LC/MS, SFC/MS, and NMR. His qualifications attracted big pharma and in 2013 he joined AstraZeneca. Mickey continued to enhance his analytical chemistry skills as part of both the Oncology and Infection Chemistry groups. In 2015, Mickey rejoined Averica taking on a Business Development role. The position offers an opportunity to use his knowledge of Averica capabilities and technical expertise to explore creative solutions to client’s problems, developing deep insight into each project’s criteria for success.